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ABSTRACT 
Proteolysis of Coronavirus spike proteins is required for virus infectivity. 
Cleavage of spike at the appropriate time and location results in efficient activation of 
viral entry into host cell. Type II transmembrane serine proteases (TTSPs), specifically, 
transmembrane protease serine 2 (TMPRSS2) when expressed on target cells, enhance 
SARS coronavirus entry by activating cleavage of spike. TMPRSS2, when expressed in 
virus producing cells, is known to proteolytically activate influenza virus HA0 and 
Human Metapneumovirus F0 glycoproteins. In this study, I investigated the effect of 
TTSPs expressed in Coronavirus producer cells. Murine Hepatitis Virus strain A59 
(MHV A59) viruses produced in the absence of TMPRSS2 were found to require the 
activity of target cell proteases - either cell surface serine proteases or endosomal 
acidophilic proteases - for entry. MHV A59 viruses produced in the presence of 
TMPRSS2 were less infectious overall, but a portion of the viruses contained “pre-
primed” S proteins and were activated for entry in the absence of target cell protease 
activity. These findings indicate that coronaviruses can be proteolytically activated either 
in virus-producing cells or target cells and the timing of spike cleavage is crucial to virus 
infectivity. 
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 CHAPTER ONE               
INTRODUCTION 
 Viruses are obligate intracellular parasites that invade cells and subsequently 
subvert the host cell machinery to complete their life cycle. Entry into host cells is 
mediated by viral surface proteins which engage with an attachment factor or virus 
receptor on the target cell surface. In the case of enveloped viruses, entry is mediated by 
surface glycoproteins [1]. Following receptor binding, enveloped viruses enter the host 
cell by membrane fusion, which occurs either at the plasma membrane or after 
endocytosis at endosomal membranes [2-4]. 
Coronaviruses are enveloped, positive-sense, single-stranded RNA viruses that 
have a broad range of tropism, infecting mammals and birds, causing respiratory, 
gastrointestinal, hepatic, kidney and brain infections. Mouse hepatitis viruses (MHVs) 
such as MHV strains A59 and 2, have been studied extensively as models for coronavirus 
biology and are known to cause hepatitis, diarrhea, respiratory infections and 
demyelinating infections of the central nervous system[5, 6] . Human coronaviruses (H-
CoVs), namely HCoV-NL-63, HCoV-229E and HCoV-OC43, cause primarily mild 
respiratory tract infections, while human SARS-CoV is notable as the most pathogenic, 
causing Severe Acute Respiratory Syndrome (SARS) [7].            
  Spike (S) proteins mediate CoV entry into host cells via receptor binding and 
membrane fusion. S glycoproteins are trimeric projections on the virus envelope and are
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the sole viral mediators of attachment and entry, and hence are central determinants of 
virulence and host tropism[8]. S proteins are synthesized at the endoplasmic reticulum 
and undergo oligomerization and carbohydrate processing during maturation through the 
cellular secretory pathway to emerge as a heavily N-glycosylated type I membrane 
proteins, assembled as trimers on the virion envelope[9]. S proteins belong to the class I 
fusion proteins, which are synthesized as precursors requiring proteolytic cleavage by 
host proteases to be activated for cell entry [1, 10, 11]. For some CoVs, such as MHV 
A59, S cleavage can occur during maturation in virus producer cells [12], while other 
CoVs, such as SARS-CoV and MHV2, are produced with uncleaved spikes[9, 13-15] that 
have to be subsequently cleaved during entry into target cells after receptor binding [16, 
17].  
Proteolytic cleavage positions the S proteins in an energy-rich metastable 
configuration, and renders them capable, upon further refolding events, of driving the 
energetically unfavorable task of drawing viral and target cell membranes in close 
apposition.  
Figure 1 provides  linear depictions of SARS CoV, MHV2 and MHV strain A59 
spike proteins and highlights domains involved in cell receptor binding (RBDs) and 
virus-cell membrane fusion  The currently known sites of proteolytic cleavage are also 
shown. 
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Figure.1 Schematic depiction of Spike proteins of SARS CoV, MHV A59 and 
MHV2:SARS CoV and MHV 2 spike proteins are synthesized as uncleaved 
glycoproteins which require target cell proteases for activation, while MHV A59 spike is 
cleaved during assembly. SARS CoV S undergoes a second activating cleavage at S2 
(R797), immediately N-terminal to its fusion peptide [61,62]. The S1 subunit contains a 
signal peptide (SP), the receptor binding domain (RBD) while the transmembrane S2 
subunit contains the fusion peptide (FP), heptad repeat (HR) sequences HR1 and HR2 
which mediate membrane fusion, a transmembrane domain (TM) and a short cytoplasmic 
tail (CT). 
 
The N-terminal subunit S1 contains a receptor binding domain (RBD).The C-
terminal S2 subunit contains a hydrophobic fusion peptide (FP), two heptad repeat 
sequences (HR1 and HR2), a transmembrane domain(TM) and a cytoplasmic tail (CT). 
The S1 subunit mediates receptor attachment via interactions between its RBD domain 
and a cellular receptor, and the S2 subunit is responsible for membrane fusion.  In the 
case of MHV, the cellular receptor is carcinoembryonic antigen-related cell adhesion 
molecule (CEACAM) [18-20] and for SARS-CoV, the receptor is angiotensin-converting 
enzyme 2 (ACE2)[21, 22]. For both viruses, binding to the receptor triggers S protein 
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conformational changes that render the S2 subunit fusogenic [23-26].Figure 2 is a model 
depicting MHV spike-mediated membrane fusion; binding of spike to its receptor 
CEACAM results in the dissociation of S1 from S2 and exposure of the fusion peptide, 
which is inserted into the target membrane. After the fusion peptide is anchored into the 
target cell membrane, the S2 subunit folds back on itself resulting in the formation of a 
six-helix bundle (6HB).This 6HB consists of a central coiled-coil formed by three HR1 
fragments surrounded by three anti-parallel HR2 helices. The formation of the 6HB 
brings the cell membrane-anchored fusion peptide close to the S2 transmembrane 
domain, thus bringing cellular and viral membrane close to each other for membrane 
fusion [12, 27-30].  
S1
S2
CEACAM
Viral Membrane
Cellular Membrane
S1
6-HB
HR2
HR1
FP
 
Figure 2. Model for coronavirus spike protein-mediated membrane fusion: ( From 
“Role of Spike Protein Endodomains in Regulating Coronavirus Entry” Shulla, A., et al., 
JBC, 2009[31]) S1 subunit of spike binds to cellular CEACAM receptor and dissociates 
from S2. After the fusion peptide (FP) is inserted into the target cell membrane, S2 folds 
on itself, allowing Heptad Repeat 2 (HR2) to bind with Heptad Repeat 1(HR1) to form a 
six-helix bundle (6-HB).The formation of the 6-HB brings the viral and cellular 
membranes in contact, facilitating membrane fusion.  
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There are a number of host cell proteases that cleave CoV S proteins. Furin-like 
proteases cleave the MHV A59 spike late in its assembly stage [32], while trypsin and 
endosomal proteases Cathepsin B and Cathepsin L are necessary for  MHV2 S- mediated 
cell entry[33]. The host cell proteases that have been implicated in mediating SARS CoV 
entry include Cathepsin L, trypsin, elastase, plasmin, thermolysin and factor Xa[17, 34, 
35]. Recent studies have also identified proteases belonging to the family of type II 
transmembrane serine proteases (TTSPs) as SARS CoV entry co-factors [36-38].  In all 
cases, the proteolytic events are thought to relieve structural constraints such that S 
proteins can undergo the dramatic conformational transitions needed to catalyze 
membrane fusions.  
TTSPs are a family of membrane anchored proteases with a broad range of tissue 
distribution and function. Though relatively recently identified, the TTSP family 
members have been observed to play diverse roles in maintaining cellular homeostasis in 
the gastrointestinal, cardiovascular and respiratory systems[39, 40].TTSPs that are 
expressed in the respiratory tract, such as TMPRSS11D (also known as  HAT: human 
airway trypsin-like protease), TMPRSS4, TMPRSS11A, and TMPRSS2, have been 
shown to activate and support multicycle replication of human influenza viruses [36, 41-
43]. TMPRSS2 can also activate and support replication of human metapneumoviruses 
(HMPV), which, like influenza viruses, are etiological agents of infectious respiratory 
tract diseases[44]. The enhancement of both influenza virus and HMPV infections by 
TMPRSS2 is due to the proteolytic activation of newly synthesized, uncleaved 
hemagglutinin (HA0) and F0 proteins, the surface glycoproteins of influenza and HMPV 
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viruses respectively[41, 44]. In light of the activating effects that TMPRSS2 exhibits 
during SARS CoV, this study set out to investigate the effects that TMPRSS2 might have 
during CoV production. 
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CHAPTER TWO                                                                                                       
METHODS 
Cells: 293T [45], 293-ACE2 (293T cells stably expressing SARS corona virus 
receptor angiotensin converting enzyme 2, ACE2) and HeLa-CEACAM (HeLa cells 
stably expressing carcinoembryonic antigen cell adhesion molecule, CEACAM [46] 
)were cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal 
calf serum (FCS), 2 mM L-Glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin 
and 0.01M sodium HEPES (pH7.4). Serum Free Media(SFM) used for plaque assay 
titration contained 2 mM L-Glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin 
and 0.01M sodium HEPES (pH7.4). Murine 17cl1 fibroblasts [47] were grown in DMEM 
supplemented with 5% tryptose phosphate broth, 5% fetal calf serum and 0.01M sodium 
HEPES (pH7.4).  
Coronaviruses: Murine coronaviruses MHV2 and recombinant MHV A59 
viruses used in this study were propagated in 17 cl1 cells. Assays for virus cell entry were 
done using recombinant MHV A59 virus, rA59EFLM, which has a firefly luciferase (FL) 
reporter gene insertion between the E and M open reading frames [48]. 
Plasmid DNAs:  Plasmids used in this study include : pNL4.3-Luc R-E (obtained 
from the NIH AIDS Research and Reference Program), encoding the HIV-1 strain NL4 
genome with firefly luciferase gene inserted into the pNL4-3 nef gene and expressing 
luciferase as marker of gene expression[49]; pcDNA 3.1 SARS S ,encoding SARS Spike, 
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obtained from Michael Farzan, Harvard Medical School, Boston, MA; pHEF-
VSV G encoding VSV glycoprotein G, from Lijun Rong, University of Illinois Chicago, 
Chicago; pcDNA 3.1 CEACAM, encoding CEACAM, the receptor for murine 
coronaviruses; Empty vector pCAGGS MCS[50];  pCAGGS-TMPRSS2-FLAG, 
pCAGGSTMPRSS11A-FLAG, pCAGGSTMPRSS11D-FLAG, encoding FLAG-tagged 
TMPRSS2, TMPRSS11A and TMPRSS11D, respectively[38]; pCAGGS A59 S 
,pCAGGS A59 E, pCAGGS A59 M, pCAGGS A59 N, encoding MHV A59 S, E , M and 
N proteins, respectively. 
Pseudo – coronavirus production:  293T cells, seeded onto 6-well plates at 
~50% confluency, were transiently transfected by the calcium phosphate precipitation 
method [51, 52], with pCAGGS MCS empty vector, or with   
0.001µg/0.003µg/0.01µg/0.03µg/0.1µg/0.3µg/1µg of pCAGGS-TMPRSS2-FLAG and 
1µg each of pNL4-3LUC-R-E, and pHEF-VSVG/ pcDNA3.1-S-SARS. 48 hours post-
transfection (h.p.t), supernatants containing secreted pseudoviruses were collected and 
clarified by centrifugation at 1000xg for 10min at 4 οC. For Western blot analysis, the 
pseudoviruses were purified by ultracentrifugation over a 30% sucrose cushion at 
55000rpm for 1hour and 15min at 4 οC using a Beckman SW60 rotor. The pelleted 
pseudovirus particles were resuspended in SDS-DTT solubilizer (0.125 M Tris [pH 6.8], 
10% dithiothreitol [DTT] , 2% sodium dodecyl sulfate [SDS], 10% sucrose, 0.004% 
bromophenol blue) and heated at 95 οC for 5min. 
Pseudo – coronavirus transduction:  For pseudovirus transduction assays, 96-
well plates were seeded with 293 ACE2 cells at a density of 4 x104 cells /well, infected 
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with the pseudoviruses, and spinoculated at 3000rpm for 90 min at 25οC. Fresh media 
was added back to the wells and the plates were incubated at 37 οC. After 48hours 
transduction, the target cells were lysed with Promega reporter lysis buffer (Cat# E397A) 
and luminescence measured upon addition of Promega Luciferase substrate (Cat#E1501) 
with a Veritas microplate luminometer.  
Production of MHV Virus-Like-Particles (VLPs): 293T cells seeded onto 6-
well plates were transiently transfected with 1µg each pCAGGS A59 S, E, M, N and 
MCS empty vector, with or without additional 0.1/1µg of pCAGGS-TMPRSS2-FLAG.  
The calcium phosphate precipitation method was used for transfection [51, 52].48 h.p.t., 
supernatants containing secreted VLPs were collected and clarified by centrifugation at 
1000xg for 10min at 4C. The VLPs were purified by ultracentrifugation through a 30% 
sucrose cushion at 55000 rpm for 1 hour and 15min at 4 οC with a Beckman SW60 rotor. 
The pelleted VLPs were resuspended in SDS-DTT solubilizer and heated at 95 οC for 5 
min for subsequent evaluation by Western Blotting. 
 Production of rA59EFLM from cells transiently expressing TMPRSS2: 
293T cells seeded onto 10cm-diameter dishes at >60% confluency were transfected with 
1µg each of pcDNA mCEACAM and pCAGGS MCS empty vector, with or without 
0.01/0.1/1µg pCAGGS TMPRSS2-FLAG.  The Polyethylenimine (PEI) transfection 
method was used [53]. 24 h.p.t, the cells were infected with rA59EFLM at an M.O.I of 
0.01. Viruses secreted in the supernatant were collected (5ml/dish) ~20 hours post-
infection (h.p.i.), clarified for 10min at 2000xg, and used for infectivity assays. Viruses in 
1ml of each clarified media were ultracentrifuged through 30% sucrose at 55000rpm for 
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1hour and 15min at 4 οC using a Beckman SW60 rotor. The pelleted viruses were 
resuspended in SDS-DTT solubilizer and heated at 95 οC for 5min for subsequent 
evaluation by Western Blotting. 
MHV2 production in cells transiently expressing TMPRSS2: 293T cells 
seeded onto 6-well (10 cm2 per well) plates at ~50% confluency were transiently 
transfected with 1µg pcDNA3.1CEACAM and pCAGGS MCS empty vector, or , 
0.01µg/0.1µg/1µg of pCAGGS-TMPRSS2-FLAG, by the calcium phosphate 
precipitation method. 24 h.p.t, the cells were infected with MHV2 virus (3x108 pfu/ml) at 
a multiplicity of infection (MOI) of 1.Viruses secreted in the supernatant (1.5ml/well) 
were collected 20hrs post-infection, and clarified by centrifugation at 1000xg for10min at 
4 οC, 100µl volumes of each clarified supernatant were used for plaque assay titration 
and1ml volumes were ultracentrifuged over 30% sucrose cushions at 55000 rpm for 1 
hour and 15 min at 4 οC using a Beckman SW60 rotor. The pelleted viruses were 
resuspended in SDS-DTT solubilizer and heated at 95 οC for 5min for subsequent 
evaluation by Western Blotting. 
MHV A59 infectivity assay in the presence of drugs: HeLa-CEACAM cells 
seeded onto 96 well plates at ~80% confluency were incubated with either complete 
DMEM media as control or 20nM Bafilomycin A1 (Sigma Aldrich Cat #B1793) in 
complete DMEM media for 30 minutes at 37οC. The cells were then treated with either 
50µM Aprotinin (Sigma Aldrich Cat # A6279), or DMEM and infected with rA59EFLM 
viruses that had been produced in cells expressing graded amounts of TMPRSS2, and the 
infection was allowed to continue in the presence of the inhibitors. After 6 hours of 
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incubation at 37οC, the infected target cells were lysed to measure luciferase 
accumulations. 
Plaque assay titration of MHV2 virus produced in cells transiently 
expressing TMPRSS2:17Cl1 cells seeded on 6-well plates were infected with 100µl 
volumes of MHV2 that had been serially diluted in serum free media. After 1 hour of 
infection at 37 οC, the infection medium was aspirated and the cells were overlaid with 
2ml/well of 1% Noble agar mixed with 2xDMEM containing 2% FCS and incubated at 
37οC. After 48 hours, the cells were fixed in 25% Formalin, stained with Crystal violet, 
and plaques were counted. 
Western blot analysis: Purified HIV pseudoviruses (HIV SARS S, HIV A59 S 
and HIV VSV G), MHVs (MHV2 and rA59EFLM) and MHV VLPs ,resuspended in 
SDS-DTT solubilizer were heated at 95οC for 5min and subjected to SDS-polyacrylamide 
gel electrophoreses (SDS-PAGE). The gels were transferred on to polyvinylidene 
difluoride (PVDF) membranes which were then blocked for 1 hour with 5% non-fat milk 
powder  in TBST (25 mM Tris-HCl {pH 7.5}, 140 mM NaCl, 2.7 mM KCl, 0.05% 
Tween 20).HIV p24 proteins were detected with mouse monoclonal  anti-p24 antibody ( 
NIH AIDS Research and Reference Program) diluted 1:5000 in TBST. SARS Spike was 
detected with anti-C9 tag (1D4) antibody (1:5000 in TBST). MHV2 and MHV A59 spike 
proteins were detected using anti S2 (10G) mouse monoclonal antibody [15, 54] (1:2000 
in TBST). MHV A59 M proteins were detected using mouse monoclonal anti-M 
J.3.1[55] antibody(1:500 in TBST).
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 CHAPTER THREE                                                                                                         
THE EFFECT OF TYPE II TRANSMEMBRANE PROTEASES ON PSEUDOVIRUS 
AND VLP PRODUCTION 
 The effects of TTSPs on pseudovirus transduction:  
  Of the 17 known human TTSPs[39], TMPRSS11A and TMPRSS11D (Human 
Airway Trypsin-like protease) and TMPRSS2 were tested for their effects on HIV-SARS 
assembly because these three are expressed in the respiratory tract and have been shown 
to proteolytically activate Influenza Hemagglutinin, Human Metapneumovirus F proteins 
and SARS-CoV Spike-mediated  entry[36, 37, 41, 44] . HIV-pseudotyped vectors 
expressing the luciferase reporter gene[56] and bearing SARS-CoV S proteins were 
produced in 293T cells that had been transiently transfected to express varying amounts 
of TMPRSS proteins. The pseudoviruses thus produced were used to transduce 293T 
cells that stably express ACE2. 2 days post-transduction, the target cells were lysed and 
luciferase accumulations were measured as readout for pseudovirus entry. Figure 3A 
presents a schematic diagram of this approach. 
The presence of TMPRSS 11A, TMPRSS11D and TMPRSS2 in the pseudovirus 
producing cells had an inactivating effect on the transducing abilities of HIV SARS 
pseudoviruses, with the effect of TMPRSS2 being most potent(Fig. 3B), hence, further 
study of TTSPs was pursued with TMPRSS2.
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When co-expressed in HIV-SARS and HIV-VSVG producing cells, increasing 
amounts of TMPRSS2 specifically inhibited HIV-SARS S- mediated transduction , while 
the transducing ability of HIV-VSVG was relatively unaffected (Fig. 4). The inhibition of 
transduction observed with HIV-SARS S also extended to another CoV pseudotype, HIV 
– MHV A59 (Fig. 5).  
293T cells transfected with
plasmids encoding HIV-Luciferase, SARS spike
and empty vector or 0.01/0.1µg/1µg TMPRSS2,
11A and 11D
HIV SARS S particles 
48hrs incubation at 37º C
293T ACE2 cells
48hrs transduction at 37º C
Target cells lysed and luciferase accumulations measured
 
Figure 3A. Schematic diagram depicting pseudovirus production and transduction: 
293T producer cells were co-transfected with 1 µg each of plasmids encoding HIV-
Luciferase, SARS S and empty vector or 0.01µg/0.1ug/1ug TMPRSS2, TMPRSS11A 
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and TMPRSS11D. Pseudoviruses collected 48 h.p.t were used to transduce 293-ACE2 
cells. 
 
L
o
g 1
0
R
L
U 4
3
2
1
01.E+00
1.E+01
1.E+02
1.E+03
1.E+04
1.E+05
1.E+06
1.E+07
6
7
5
0 µg 0.01 µg 0.1 µg 1 µg
TMPRSS (µg)
TMPRSS2                              TMPRSS11A                          TMPRSS11D
Figure 3B. Effect of TTSPs 2, 11A and 11D on HIV-SARS S transduction: Luciferase 
values measured 2 days post-transduction were plotted on a Log10 scale. The error bars 
represent standard deviations.  
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Figure 4. TMPRSS2 dose-response: Transduction abilities of HIV-SARS S and 
HIV- VSV G pseudoviruses produced in cells expressing graded amounts of 
TMPRSS2: HIV-SARS S and HIV-VSV G pseudoviruses were produced by co-
transfecting 293T cells with HIV vector, HIV-SARS S or HIV-VSV G vector and 
pCAGGS Empty Vector or the indicated amounts of pCAGGS TMPRSS2-FLAG. 48 
h.p.t, media containing the pseudoviruses were collected and used to transduce target 
293T-ACE2 cells. Target cells were lysed 2 days post-transduction and luciferase 
accumulations were measured. The error bars represent one standard deviation above and 
below the mean.  
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Figure 5. Transduction ability of HIV-MHV A59 S pseudoviruses produced in cells 
expressing TMPRSS2: HIV-A59 S pseudoviruses were produced by co-transfecting 
293T cells with HIV vector, MHV A59 S vector and pCAGGS Empty Vector or the 
indicated amounts of pCAGGS TMPRSS2-FLAG. The pseudoviruses were used to 
transduce target HeLa-CEACAM cells which were lysed 2 days post-transduction and 
measured for luciferase accumulations. The error bars represent one standard deviation 
above and below the mean. 
 
The effect of TMPRSS2 on HIV SARS S and HIV A59 S protein cleavage: 
 The dramatic reduction in transduction potential mediated by TMPRSS2 (Figs. 4 
and 5) suggested that TMPRSS2 might degrade CoV S proteins during pseudovirus 
assembly and / or secretion. 
To test this hypothesis, the HIV-SARS S and HIV-MHV A59 S pseudoparticles that were 
evaluated for transduction potential (Figs.4 and 5) were purified by ultracentrifugation 
and evaluated for S protein cleavage by Western immunoblotting.   
17 
 
 
The data (Fig. 6) revealed that both SARS and MHV A59 S proteins were 
degraded with increasing doses of TMPRSS2, with the degree of degradation 
corresponding to the decreases in transducing abilities. 
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Figure 6.  S cleavage on HIV-SARS S and HIV-A59 S pseudoviruses: HIV SARS S 
and HIV A59 S pseudoviruses produced in 293T cells transfected with the indicated 
amounts of pCAGGS TMPRSS2-FLAG were purified by ultracentrifugation. 
Resuspended pseudoviruses were evaluated by western immunoblotting for HIV p24 
(anti-p24 antibody) and SARS S (anti-C9 antibody) or MHV A59 Spike (10G anti-S2 
antibody) 
 
The effect of TMPRSS2 on MHV VLP production:  
HIV pseudoviruses bud at the plasma membrane, where TMPRSS2 is expressed 
[57, 58], whereas authentic coronaviruses bud intracellularly at the ER-Golgi-
Intermediate-Compartment (ERGIC) [9, 59]. The degradation of HIV–CoV spikes 
observed in Fig. 6 could have occurred during pseudovirus budding from the cell surface, 
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where the spikes may be readily accessible to TMPRSS2.To determine if the site of spike 
assembly plays a role in determining its susceptibility to the protease, I utilized MHV 
A59 virus-like-particles (VLPs), and compared the effect of TMPRSS2 on spikes that 
were either assembled on the plasma membrane or intracellularly at the ERGIC. MHV S 
proteins, when expressed alone, are transported to the plasma membrane, while the co-
expression of MHV structural proteins S, E, M and N can result in the self-assembly of 
VLPs at the ERGIC [60, 61]. MHV VLP assembly mimics authentic virus assembly and 
the secreted particles resemble authentic viruses, but the VLPs are not infectious because 
they do not express viral genetic materials. This property makes the VLPs a good system 
to more accurately assess coronavirus assembly in cells expressing TMPRSS2.  
Briefly, 293T cells were co-transfected with plasmids encoding TMPRSS2 and 
either MHV A59 S alone, or S in combination with E, M and N. Cell lysates (expressing 
S alone) and secreted VLPs were evaluated for spike cleavage by immunoblotting. 
 The data (Fig. 7) revealed that spike proteins on MHV VLPs were degraded by 
TMPRSS2, similar to the S degradation expressed alone in cells. The susceptibility of 
MHV VLP spikes to TMPRSS2-mediated cleavage suggests that spikes are degraded 
during their assembly in the exocytic pathway.  Indeed, both TMPRSS2 and the S 
proteins are thought to co-exist in the ER, Golgi and secretory vesicles comprising the 
exocytic pathway.  Possibly S cleavages take place internally in one or more of these 
subcellular compartments. 
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Figure 7.  S cleavage on MHV A59 VLPs: MHV A59 VLPs were produced by co-
transfecting 293T cells with MHV A59 S, E, M, N vectors and pCAGSS Empty Vector 
or the indicated amounts of pCAGGS TMPRSS2-FLAG. VLPs produced were purified 
by ultracentrifugation and evaluated by Western Immunoblotting for MHV A59 S and M 
proteins with 10G (anti-S2) and anti-M J3.1 antibodies.
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CHAPTER FOUR 
 
TMPRSS2 AND AUTHENTIC CORONAVIRUS ASSEMBLY 
 
 Infectivity of MHV A59 viruses produced in TMPRSS2-expressing cells: 
 Data in the previous chapter revealed that HIV-CoV pseudoviruses secreted from 
cells expressing TMPRSS2 have greatly diminished transduction potential. The effect of 
TMPRSS2 on the production of authentic coronaviruses (murine coronaviruses 
rA59EFLM and MHV 2) was investigated next.  Here we used rA59EFLM, which 
encodes the firefly luciferase gene within its genome, making assay of the luciferase 
accumulated in infected target cells a good measure of viral entry and infectivity. 
  Fig.8A illustrates the overall experimental approach. Briefly, 293T cells that were 
co-transfected to express CEACAM (the MHV receptor) and TMPRSS2 were 
subsequently infected with rA59EFLM viruses. Progeny viruses secreted in the media 
were collected ~20 h.p.i and used to infect HeLa-CEACAM target cells. Luciferase 
accumulations were measured in the target cells at 6 hours post-infection to assess virus 
entry.  
Although the effect of TMPRSS2 on authentic MHV infectivities (Fig.8B) was 
not as dramatic as its effect on HIV A59 pseudovirus transduction, there was about a 2-
log reduction in virus infectivity.  The data indicated that viruses exiting cells over-
expressing TMPRSS2 have reduced infectivities.
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Fig 8A.Schematic diagram of production and infectivity assay of rA59EFLM viruses 
in the presence of TMPRSS2: 293T cells were co-transfected with plasmids encoding 
murine CEACAM receptor and empty vector or 0.01µg/0.1 µg/1 µg TMPRSS2. 24 h.p.t, 
the cells were infected with rA59EFLM at an M.O.I of 0.01. Viruses secreted in the 
supernatant were collected 20 h.p.i. and used to infect target HeLa-CEACAM cells. 
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Figure 8B.Infectivity of rA59EFLM viruses produced in cells expressing TMPRSS2: 
Luciferase values measured 6 h.p.i in HeLa-CEACAM  target cells were plotted on a 
Log10 scale. The error bars represent one standard deviation above and below the mean. 
 
  MHV S cleavage by TMPRSS2: 
The reduced infectivity of rA59EFLM produced from TMPRSS2-expressing cells 
(Fig. 8B) suggested that S proteins were degraded during virus maturation. To determine 
if that was the case, rA59EFLM viruses were purified by ultracentrifugation and 
evaluated for S cleavage by Western immunoblotting (Fig. 9). Spike was detected by 10G 
antibody which recognizes the HR2 region of S2, as depicted in Figure 9A. 
The data in Figure 9B revealed that increasing amounts of TMPRSS2 in producer 
cells degraded S proteins, in correlation with decreased infectivities observed (Fig.8B). 
The viruses contained spikes that had been cleaved into ~80kDa, 72kDa, 70kDa and 
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50kDa C-terminal fragments. An arginine at the P1 position is required for TMPRSS2 
cleavage [39] and there are six arginine residues in the ~ 250 amino acid region between 
S1/S2 and FP in the MHV S proteins. The 80kDa, 72kDa and 70kDa fragments observed 
in Fig 9B correspond to TMPRSS2-mediated cleavages at sites (colored arrows in Fig 
9A) lying between the well-known S1/S2 cleavage site (white arrow in Fig. 9A) and the 
FP (black bar in Fig. 9A) and the 50kDa fragment corresponds to cleavage  at a site C-
terminal to the FP .    
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Figure 9.  MHV A59 S cleavage by TMPRSS2: (A) Schematic structure of spike: S 
protein has a signal peptide (SP), receptor binding domain (RBD, a fusion peptide (FP), 
two heptad repeats (HR1and HR2), a transmembrane domain TM and a cytoplasmic tail 
(CT). The S1/S2 cleavage site is depicted by the white arrow and the black arrow depicts 
the epitopes recognized by the 10G(anti-S2) antibody. The arginine residues between the 
S1/S2 cleavage site and the FP are indicated. The possible TMPRSS2 cleavage sites 
resulting in the p80, p72, p70 and p50 fragments are indicated with colored arrows.(B) 
rA59EFLM viruses produced from 293T cells that were co-transfected with 1µg of 
pcDNA mCEACAM and the indicated amounts of pCAGGS TMPRSS2-FLAG or 
pCAGGS Empty Vector were purified by ultracentrifugation. Resuspended viruses were 
evaluated by western immunoblotting for S (10G antibody) and M (anti-M antibody). 
 
 MHV A59 activation by TMPRSS2 in virus –producing cells: 
Recent reports [62-64] have indicated that the CoV S1/S2 cleavage may be 
insufficient for fusion activation, and that the S1/S2 cut is followed by a second cleavage 
at a site next to the fusion peptide, termed the S2cleavage site.  This S2’ cleavage is 
thought to be the most biologically relevant scission, because it lies immediately N-
terminal to the fusion peptide and thus would put the fusion peptide at the extremity of 
the transmembrane cleavage product.  Thus the S2 cleavage would make the CoV S 
proteins much like the traditional class I membrane fusion proteins that have their FPs at 
termini.  The 70kDa (Fig.9B) cleavage fragments observed on rA59EFLM spikes from 
TMPRSS2-expressing cells could correspond to such fragments cleaved at the vicinity of 
the fusion peptide, suggesting that a portion of the viruses expelled from TMPRSS2-
expressing cells may have “pre-activated” spikes ready to be inserted into target cell 
membranes . Entry into cells by such viruses may be insensitive to inhibitors of 
endosomal or cell surface proteases. To test this hypothesis, rA59EFLM viruses produced 
from TMPRSS2-expressing 293T cells were used to infect target cells in the presence of 
aprotinin (a membrane impermeable serine protease inhibitor [37, 65]), and/or 
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bafilomycin A1 (an ATPase inhibitor which prevents the endosomal acidification 
required for activity of some endosomal proteases [4, 66, 67]). Entry achieved by these 
viruses was compared to the entry of viruses produced from cells (293T and 17Cl1) that 
were not transfected with TMPRSS2 plasmids. 
The results (Figs. 10A and B) revealed that MHV A59 viruses produced in cells 
expressing TMPRSS2 were relatively resistant to aprotinin and bafilomycin. In the 
presence of aprotinin, control viruses, produced from cells lacking exogenous TMPRSS2, 
were inhibited by ~160-fold ( Fig. 10A)  to 1000-fold (Fig. 10B) while the viruses 
produced from cells overexpressing TMPRSS2 cells showed only 2-fold inhibition. This 
indicated that MHV A59 viruses secreted from cells in the absence of TMPRSS2 are not 
fully activated for entry and require target cell proteases (endosomal proteases or cell 
surface serine proteases) for further activation, whereas TMPRSS2,in virus producer cells 
could provide the activating proteolysis required for entry. 
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Figure 10A.Effect of Bafilomycin and Aprotinin on the entry of rA59EFLM 
virusesthat were produced in the presence of graded amounts of TMPRSS2: 
rA59EFLM viruses that had been produced in 293T cells in the presence of the indicated 
amounts of pCAGGS TMPRSS2-FLAG were used to infect target HeLa-CEACAM cells 
in the presence of complete DMEM media (No drugs) or 20nM Bafilomycin A1 and/or 
50µM Aprotinin. Cells were lysed 6 h.p.i and luciferase accumulations were measured. 
Error bars represent one standard deviation above and below the mean. 
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Figure 10B. Effect of Bafilomycin and Aprotinin on rA59EFLM entry: 
rA59EFLM viruses that were produced in 17Cl1 cells in the absence of TMPRSS2 were 
used to infect HeLa-CEACAM cells in complete DMEM media (No Treatment) or 20nM 
Bafilomycin A1 and/or 50µM Aprotinin. Cells were lysed 6 h.p.i and assayed for 
luciferase accumulations. Error bars represent one standard deviation above and below 
the mean. 
  
  Thermal inactivation of MHV A59 viruses produced in TMPRSS2-expressing cells: 
  Stability of  S1-S2 interactions have been correlated to thermal stability of  some 
strains of MHV, specifically, the  neurovirulent MHV JHM.San Diego (JMH.SD)[68]. 
JHM.SD spikes are cleaved at the S1-S2 junction. The non-covalent interaction between 
the two subunits is dissolved by elevated pH at the cell surface, and S1 dissociates 
spontaneously from S2 [69, 70] , rendering the virus in a fusion-competent state. The 
dissociation of S1 from S2 correlates with enhanced neurovirulence, and also tissue 
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culture instability [8].  Evidence of rA59EFLM spike cleavage by TMPRSS2 at positions 
near the fusion peptide (Fig. 9B, note ~ 70 kDa bands) suggested that these extra 
cleavages might render the viruses thermally labile, similar to the JHM.SD viruses.  To 
test this hypothesis, rA59EFLM viruses were incubated at 37οC for 5,10,20,40, 80min, 
and then used to infect target HeLa-CEACAM cells. At 6 hpi, target cells were lysed to 
measure luciferase accumulations. 
The data (Fig. 11) indicated that the MHV A59 viruses expelled from cells 
expressing TMPRSS2 were indeed hyperlabile. Perhaps the preactivated viruses with 
cleaved spikes undergo more rapid intrinsic denaturation over time, resulting in rapidly 
declining infectivities.   
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Figure 11. Thermal inactivation of rA59EFLM viruses produced in the presence of 
TMPRSS2: rA59EFLM viruses that were produced in the presence of the indicated 
amounts of pCAGGS TMPRSS2-FLAG were incubated at 37οC for 0, 5,10,20,40 and 80 
minutes. The viruses were then used to infect HeLa-CEACAM cells. Cells were lysed 6 
h.p.i to assay for luciferase accumulations. 
 
 Infectivity and Spike-cleavage of MHV2 viruses produced in TMPRSS2-expressing 
cells: 
  MHV2 spikes, like SARS-CoV spikes, are produced uncleaved during assembly 
and secretion from infected cells. Production of MHV2 viruses in TMPRSS2-expressing 
cells could give insight to the infectivity of SARS-CoVs produced under similar 
conditions. 
  To test the effect of TMPRSS2 on MHV2 production, MHV2 viruses were used 
to infect 293T cells that were transfected to express murine CEACAM receptor and 
TMPRSS2. Progeny viruses secreted in the media were collected 20 hpi and titered on 
17Cl1 cells to assay infectivity. Purified viruses were evaluated for S cleavage by 
Western Immunoblotting using anti-S2 (10G) antibody, which recognizes epitopes in the 
HR2 region of  the  C-terminal S2 subunit (illustrated in Fig. 12C). 
The results (Fig. 12) revealed that MHV2 viruses produced in the presence of 
TMPRSS2 were about 20-fold less infectious than control viruses that were produced in 
the absence of the protease. The presence of TMPRSS2 in producer cells seemed to result 
in an inactivating cleavage of MHV2 spike at a site C-terminal to the fusion peptide (red 
arrow in Figure 12C), to a ~55kDa product corresponding to the protease-resistant core of 
the six-helix bundle conformation (6HB) formed during membrane fusion events.    
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Figure 12. Effect of TMPRSS2 on the infectivity and Spike cleavage of MHV2 
viruses: MHV2 viruses were produced in 293T cells that were co-transfected with 1µg of 
pcDNA mCEACAM and the indicated amounts of pCAGGS TMPRSS2-FLAG or 
pCAGGS Empty Vector. A) Viruses secreted in the media were clarified by 
centrifugation and titered on 17Cl1 cells by plaque assay.B) Viruses were pelleted by 
ultracentrifugation, resuspended, and evaluated by western immunoblotting for MHV2 
Spike protein (10G anti-S2 antibody). C) Schematic depiction of MHV2 spike [15] with 
the 10G antibody recognition site (black arrow) and the putative TMPRSS2 cleavage site 
(R939, red arrow)) C-terminal to the fusion peptide (FP).  
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 CHAPTER FIVE 
CONCLUSION 
Coronavirus spike is an important determinant of viral tropism. The 
spatiotemporal sequence of spike cleavage is extremely important to viral pathogenicity 
and the proteolytic processing that spike undergoes can differ between different 
coronaviruses. SARS coronavirus spike is synthesized uncleaved and during entry; after 
receptor attachment the spike undergoes sequential cleavage at the S1-S2 junction 
(Fig.13, “1”), followed by cleavage at the S2 region (Fig 12.” 2”)  [62]. The S2 
cleavage exposes its internal fusion peptide which gets inserted to the target cell 
membrane [63]. 
12551 HR1FP HR2 TM
Uncleaved S
S1                                     S1-S2                              S2
1 2
R797 /S2
317
ACE2 RBD
510
NH2 COOHSP CT
 
Fig.13. Schematic depiction of sequential proteolytic cleavage of SARS CoV 
spike[62]: Cleavage at the S1/S2 boundary facilitates cleavage at the S2 position 
exposing the fusion peptide which can then be inserted into the target membrane for 
membrane fusion to occur.(FP: Fusion peptide; HR1: Heptad repeat 1; TM: 
Transmembrane domain) 
 
  MHV2, like SARS CoV, emerges from cells with uncleaved spikes. Engagement 
of the virus with CEACAM on a target cell, triggers stepwise conformational changes in 
spike[15, 24] which begin with the exposure of the viral fusion peptide .The insertion of 
the fusion peptide  into the cell membrane results in a pre-hairpin trimer with one end  
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embedded in the cell membrane and the other in the viral envelope. Protease-mediated 
cleavage results in a fusogenic fragment containing the fusion peptide, HR1 and HR2 and 
the transmembrane domain, triggering the next step of conformation changes. Formation 
of the 6-helix bundle (6HB), characterized by a proteinase K-resistant core appearing as a 
~53kDa band in western blot images[15], draws the two membranes close together 
resulting eventually in membrane fusion as depicted in Figure 2.  
  MHV2 viruses produced in TMPRSS2 expressing cells are less infectious (Fig12, 
left panel) but the cleavage pattern of spikes on these viruses is different from that 
observed in MHV A59 spikes. In producer cells that do not express TMPRSS2, MHV2 
spike is synthesized and assembled in an uncleaved form on the emerging virion but 
when producer cells express TMPRSS2, the spikes on the emerging viruses are cleaved 
and appear as a ~55kDa band (Fig 12, right panel) which corresponds to the proteinase-K 
resistant core of the 6-helix bundle (6HB) usually formed during fusion events after the 
interaction of spike with its receptor.  It is possible, that as in the case of SARS Spike, the 
timing of MHV2 spike cleavage is crucial in virus infectivity. Spike cleavage in MHV2 
during virus production probably occurs in the absence of receptor engagement and hence 
could be an inactivating cleavage event. But, during MHV2 entry, when the virus is 
bound to its cell-surface receptor, the ensuing conformation changes of spike could 
expose previously hidden, potentially activating TMPRSS2-cleavage site(s). Cleavage at 
the newly exposed site(s) of spike by TMPRSS2, expressed on the virus-target cell, could 
therefore possibly be an entry-activating event. 
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Unlike MHV2 and SARS-CoV, MHV A59 spikes are synthesized precleaved at 
S1/S2 during biogenesis. This study reveals that the intracellular MHV A59 S cleavage is 
not the only activating step required for successful infection (Fig 10A and B). Spike 
requires further cleavage, perhaps at or near the S2 region, by either cell surface serine 
or endosomal acidophilic proteases, since inhibition of these proteases resulted in a 
decrease in viral entry of up to a 1000-fold . The extents of inhibition by either the serine 
protease inhibitor aprotinin or the endosomal protease inhibitor bafilomycin further 
suggests that on entering target cells, the viruses can undergo two different, independent 
activation pathways. About two-thirds of the entering viruses can get activated at cell 
surfaces by serine-proteases that are inhibited by aprotinin. The other one-third of the 
entering viruses do not get activated in this way and are then activated in endosomes by 
acidophilic proteases, likely cathepsins, that are inhibited by bafilomycin. Either of the 
two activation processes are sufficient for virus entry – the aprotinin-sensitive activation 
does not require additional bafilomycin-sensitive activation and vice versa.  The action of 
these proteases could result in cleavage at the S2 region, exposing the fusion peptide 
for subsequent insertion into target cell membranes as depicted in Fig.14. 
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Figure 14 .Model for MHV A59 entry effects of proteases on target cells:  Figure 
modified from “Role of Spike Protein Endodomains in Regulating Coronavirus Entry” 
Shulla, A., et al., JBC, 2009[31] . Conformation change occurring upon receptor binding 
by the S1 subunit of MHV spike exposes the S2 cleavage site to the action of target cells 
proteases. Cleavage at the S2 site (middle panel) exposes the fusion peptide (FP) which 
is inserted into the cell membrane forming the prehairpin trimer intermediate.  
 
  Viruses emerging from TMPRSS2 expressing cells were less stable (Fig 11), had 
lower infectivities (Fig8B) and appeared to be relatively resistant to aprotinin (Fig. 10A). 
It is possible that a portion of the viruses secreted from TMPRSS2 expressing cells bear 
spikes that have been cleaved at the S2 cleavage site and have their fusion peptides 
exposed and pre-primed for target cell membrane insertion. The 70kDa S2 fragments that 
appear in viruses from TMPRSS2 positive cells (Fig 9) could correspond to the pre-
primed S2 fragments which do not need further activation by target cell proteases and 
hence are insensitive to protease inhibition. On the other hand, while some viruses are 
secreted with pre-primed spikes, it appears that another fraction of the progeny virions 
have inactivating spike cleavage with S2 fragments ~50kDa in size which also 
corresponds to the overall lowered infectivities  of viruses emerging from TMPRSS2 
expressing cells.   
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Fig.15 depicts a model for the effects of TMPRSS2 protease activity on MHV 
production. In an infected cell, progeny MHV virion morphogenesis occurs by budding at 
the ERGIC. It is possible that during maturation and egress through the compartments of 
the host cell secretory pathway, the viruses come in contact with newly synthesized 
TMPRSS2 proteins being transported to the plasma membrane. The proximity of protease 
and substrate within the same intracellular compartments likely facilitates TMPRSS2-
mediated cleavage of accessible spikes into the ~ 80kDa, 72kDa, 70kDa and 50kDa 
fragments observed in the western blot image in Fig 9B. It is not clear, however, whether 
the TMPRSS2-mediated cleavage affects the non-covalent interactions between S1 and 
S2 and whether the cleaved spikes on the expelled viruses are maintained as stable S1-S2 
complexes.  
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Figure 15. Model for TMPRSS2 effects on MHV production:  In an infected cell, 
nascent MHV virions and newly synthesized TMPRSS2 proteins are transported together 
to the cell surface by secretory vesicles of the exocytic pathway. Transport in the same 
intracellular compartments renders spike proteins on the virions accessible to the 
proteolytic activities of TMPRSS2 and viruses emerge from the cells bearing cleaved 
spikes. 
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It is conceivable that cleavage by TMPRSS2 in MHV- producer cells results in 
the loss of segments of spike that are important for stable S1-S2 interaction. The 
decreased thermo-stability observed in these viruses (Fig.11) could be a consequence of a 
decreased stability in S1-S2 interactions causing spontaneous S1 detachment not unlike 
that observed in MHV JHM.SD [8, 68, 69].       
Proteases play a crucial role in coronavirus spike activation and the timing and 
location of the cleavage can make the difference between an activating and an 
inactivating cleavage. Unlike influenza and HMPV viruses, which are activated in 
producer cells by TMPRSS2 mediated cleavage of their precursor glycoproteins during 
transit through the cellular exocytic pathway, MHV coronaviruses emerging from 
TMPRSS2-expressing cells are overall less infectious and are subject to inactivating 
spike cleavage. The “pre-priming” of some MHV A59 viruses by TMPRSS2 in the 
producer cells is balanced by the inactivating spike cleavage of some emerging viruses.  
The findings from this study have implications for the study of host cell factors 
that play a role in coronavirus infection and evolution. Collectively, the data indicate that 
the coronavirus entry activation that is facilitated by TMPRSS2 [38] might be tempered 
by the subsequent inactivation of progeny viruses by the proteases, possibly as a 
mechanism of host cell resistance. Development of host cell resistance can necessitate co-
evolution of viruses to select for more virulent variants as a mechanism to establish 
persistent infection [71-73].  It is conceivable that serial passaging of coronaviruses in 
cells expressing TMPRSS2 could result in the emergence of mutations in the inactivating 
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cleavage sites recognized by the protease thus producing more virulent TMPRSS2-
resistent viruses
  
[39] 
 
                                                 
 
 
 
 
 
 
 
                                                APPENDIX 
EFFECT OF ANTI VIRAL LECTIN GRIFFITHSIN ON CORONAVIRUS 
INFECTION
[40] 
 
 
Griffithsin (GFRT) is a mannose binding plant lectin with potent anti-viral 
  properties that was isolated from red algae Griffithsia in New Zealand in 
 2004, during an NCI, National Institutes of Health sponsored search for 
  natural product extracts exhibiting anti-HIV activity [75]. Lectins are  
  commonly occurring proteins in nature that bind carbohydrates and play 
 varied roles in cellular processes. The propensity of lectins to bind  
 carbohydrates makes them attractive candidates for antiviral agents since 
 enveloped viruses such as retroviruses and coronaviruses are embedded 
 with heavily glycosylated surface glycoproteins, which when targeted can 
 lead to disruption of the virus-host cell interactions and inhibit virus 
 entry[74].                                                                                         
 GFRT binds to oligosaccharides on HIV gp120 and inhibits cytopathic 
 effects of HIV-1 at picomolar concentrations, without having cytotoxic 
 effects on cells at high concentrations, indicating its promise as a potential 
 anti-viral microbicide [75].       
 A recent study indicates that GFRT mediated inhibition extends to 
 coronaviruses and intranasal administration of the lectin prevents lethal 
 pulmonary infection in mice [76]. The goal of this study was a better 
 understanding of the mechanism of action of GFRT, which could aid in 
 the development of preventative and therapeutic measures such as topical 
 anti-viral microbicides. 
Methods                                                                                                                         
Cells and viruses                                                                                                                     
  The cell lines used in this study,293T cells and HeLa-CD4 cells stably  
  transfected to express CD4[77], were cultured in DMEM supplemented  
  with 10%FBS, 2mM L-Glutamine, 100 units/ml penicillin, 100µg/ml  
  streptomycin and 0.01M sodium HEPES (pH7.4). Murine 17cl1   
  fibroblasts used to passage MHV A59 viruses were grown in media  
  containing DMEM , 5% tryptose phosphate broth, 5% FCS and 0.01M  
  sodium HEPES (pH7.4). SFM used in pseudovirus transduction and cell- 
  cell fusion assays contained 2mM L-Glutamine, 100 units/ml penicillin,  
  100µg/ml streptomycin and 0.01M sodium HEPES (pH7.4). 
Plasmid DNAs                                                                                                                    
   plasmids used in the study included, pNL4-3LUC-R-E( encoding the  
  HIV-1 strain NL4 genome with firefly luciferase gene inserted into the  
  pNL4-3 nef gene and expressing luciferase as marker of gene   
  expression[49]), pcDNA 3.1 CEACAM (encoding CEACAM the receptor  
  for MHVs), pHEF-VSV G (encoding VSV glycoprotein G), pCAGGS  
  A59 S (encoding MHV A59 S) , pCAG T7pol (encoding T7 RNA   
  polymerase), pT7EMC-luc (encoding firefly luciferase under the control  
  of T7 RNA polymerase promoter.   
Pseudovirus transductions                                                                                             
   HIV-pseudotyped virions were produced by co-transfecting 293T cells,  
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  via calcium phosphate, with pNL4-3LUC-R-E, and plasmid vectors  
  encoding MHV A59 S/VSV G/gp120/41 from HIV-1 JR-FL strain.  
  Pseudovirions secreted in the media were collected 48 hpi, clarified at  
  2000xg for 10min, 4οC and stored at -20 οC. For transductions, target  
  HeLa-CD4 cells were transfected, via lipofection[78] (using   
  LipofectamineTM  2000 transfection reagent, Invitrogen), with pcDNA  
  CEACAM. 24 hpt, the target cells were incubated with either SFM or  
  100nM, 200nM, 400nM Griffithsin (obtained from the NIH AIDS   
  Research and Reference Program) in SFM, for 20min at 22 οC. After  
  20min, the media was aspirated, pseudovirions were added and the plates  
  were spinoculated by centrifugation at 25 οC for 2 hours at 3000rpm.  
  After 2 days of transduction at 37 οC, the target cells were lysed and  
  luciferase activity measured.  
Cell-cell fusion assay                                                                                           
    Target 293T cells were co-transfected with pcDNA3.1 CEACAM and 
   pT7EMC-luc via calcium phosphate. Effector cells were produced by co- 
  transfecting 293T cells with pCAGGS A59 S and pCAG-T7pol via  
  calcium phosphate. 28 hours post transfection, effector cells were   
  resuspended in serum free media (SFM) and overlaid on the target cells at  
  a 1:1 ratio and spinoculated at 500xg for 5min, at 4οC.100nM, 200nM,  
  400nM Griffithsin in SFM, or SFM alone, was added and the cells were  
  incubated at 37οC. After 4 hours, the cells were lysed and assayed for  
  luciferase accumulations. 
Immunoprecipitation and immunoblotting                                            
  nCEACAM-Fc proteins[23] and protein G magnetic beads were   
  resuspended in HN buffer (25 mM Na Hepes, 150 mM NaCl )and   
  incubated at 22 οC for 1 hour. The beads were rinsed thrice with HNB  
  buffer (25 mM Na Hepes, 150 mM NaCl, 0.01% BSA) containing 0.5%  
  sodium deoxycholate, 0.5% NP40 to wash away unbound nCEACAM-Fc  
  proteins. The beads were then incubated with SFM (No GFRT), or  
  100nM, 200nM, 400nM GFRT in SFM at 22 οC for 20min.After rinsing  
  thrice with HNB buffer, the beads were incubated with MHV A59 viruses  
  at 37 οC for 1 hour. The beads were rinsed thrice in HNB and the proteins  
  were eluted from the beads by adding SDS-DTT solubilizer (.125 M Tris 
  {pH 6.8}, 10% dithiothreitol, 2% sodium dodecyl sulfate [SDS], 10%  
  sucrose, 0.004% bromophenol blue), and heating at 95 οC for 5min. The  
  samples were subjected to 12% SDS polyacrylamide gel electrophoresis 
  and the gels were transferred to polyvinylidine difluoride membranes  
  which were then blocked for 1 hour with 5% non-fat milk powder in 
  TBST (25 mM Tris-HCl {pH 7.5}, 140 mM NaCl, 2.7 mM KCl, 0.05%  
  Tween 20). Spike proteins were detected using monoclonal, anti-S2 (10G) 
  antibody (1:2000 in 2% milk in TBST), and GFRT was detected using 
  anti-GFRT antibody (1:1000 in 2% milk in TBST). 
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Results                                                                                                                          
Effect of GFRT on pseudovirus transductions                                               
   The effect of GFRT on coronavirus infections was examined using HIV- 
    pseudotyped MHV A59 S pseudoparticles in HeLa-CD4 cells transiently 
    expressing CEACAM receptor. Briefly, HIV-A59 S, HIV-VSV G and  
    HIV –JR-FL  pseudoviruses were used to transduce HeLa-CD4 target  
    cells in the presence of increasing amounts of GFRT. 48 hours post- 
    transduction, the target cells were lysed and assayed for luciferase 
    activities. HIV-JR-FL was used as a positive control, since the inhibitory 
    effect of GFRT on HIV has been documented [75]. The results (Fig 16) 
    revealed that the transduction  ability of HIV-A59 S was decreased  
    almost 10-fold by Griffithsin, and this effect was specific to   
    coronaviruses since transduction potential of HIV-VSV G was not  
    affected. 
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Figure16.Effect of GFRT on HIV-MHV A59 S pseudovirus transduction: HeLa-CD4 
cells transfected to express CEACAM receptor were incubated with 100nM, 200nM, 
400nM GFRT in serum free media for 20min at 22οC. Media was removed and the cells 
were incubated with HIV-SARS S, HIV-VSV G and HIV-JR-FL for 2 days at 37 οC. 48 
hours post-transduction, cells were lysed and luciferase activity was measured. Error bars 
represent one standard deviation above and below the mean. 
 
Effect of GFRT on virus: receptor interaction                                                      
   To determine whether GFRT blocks virus-receptor interaction, a co- 
    immunoprecipitation experiment was performed using an Fc-tagged, 
[43] 
 
 
    soluble form of CEACAM, the receptor for MHV A59, nCEACAM-Fc   
    [18, 23].  nCEACAM-Fc was captured on to protein G magnetic beads  
    and incubated with or without GFRT. MHV A59 viruses were then added 
    and after a one hour incubation period, proteins were subsequently eluted 
    from the beads and subjected to immunoblotting to detect Spike   
    proteins.The results revealed that GFRT bound CEACAM (Fig.17, lane  
    5), but did not inhibit the subsequent binding of the virion with the  
    receptor, even at higher concentrations (Fig 17, lanes 2, 3 and 4). The  
    data indicates that the site of action of GFRT is not at the stage of virus- 
    receptor binding.                                   
 
 
Figure 17: Effect of GFRT on virus-receptor binding: nCEACAM-Fc, the soluble 
form of the receptor for MHV A59, bound to Protein A magnetic beads, was incubated 
with the indicated concentrations of GFRT (Griffithsin) at 37ºC for 30min, washed, 
followed by incubation with purified, wild type MHV A59 virus for 30 min at 37 ºC.The 
samples were analyzed by SDS-PAGE and Western blotting with the indicated 
antibodies. Lanes 6 and 7 are controls to ensure that GFRT and MHV A59 are not 
binding the magnetic beads. Lanes 8 and 9 are GFRT and MHV A59 loading controls, 
respectively. 
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Figure 18.Effect of GFRT on MHV A59 Spike-mediated cell-cell fusion:  Target cells 
(293T cells transfected with plasmids encoding CEACAM and Luciferase) were overlaid, 
28hrs post-transfection, with Effector cells (293T cells transfected with plasmids 
encoding MHV A59 Spike protein and T7 Polymerase) at 1:1 ratio and spinoculated at 4 
ºC for 5min to facilitate Effector-Target cell contact without the initiation of fusion. The 
indicated concentrations of Griffithsin (GFRT) were then added, and the Effector-Target 
cells were co-incubated at 37 ºC for 4hrs, lysed and assayed for Luciferase activity. Error 
bars represent one standard deviation above and below the mean.  
 
Effect of GFRT on MHV A59 Spike mediated cell-cell fusion                              
  Data from Fig 17 indicated that GFRT may be exerting its MHV A59  
  entry inhibiting effects at post-receptor-binding stages. To determine if  
  that was the case, MHV A59 S mediated cell-cell fusion assay was  
  performed in the presence of GFRT which was administered after ensuring 
  spike-CEACAM binding. Briefly, target cells were co-transfected with  
  plasmids encoding CEACAM and a luciferase reporter under the control  
  of T7 RNA polymerase promoter. Effector cells were co-transfected to  
  express MHV A59 S, and T7 RNA polymerase. At 28 hpt, the target cells  
  were overlaid with effector cells at a 1:1 ratio and spinoculated to facilitate 
  spike-CEACAM binding. The spinoculation was performed at 4 ºC, a  
  temperature that arrests receptor-mediated spike conformational changes  
  and membrane fusion [24]. GFRT was then added to the cells and the  
  reaction shifted to 37 ºC to allow for cell-cell fusion. Cells were lysed after 
  a 4 hour co-culture and assayed for luciferase accumulations. As shown in  
  Figure 18, GFRT inhibited MHV A59 Spike mediated cell-cell fusion in a  
  concentration dependent manner. In this experiment, the effector cells  
[45] 
 
 
  bearing the MHV Spike protein were overlaid on the CEACAM receptor- 
  bearing target cells and spinoculated at 4 ºC (to ensure spike-receptor  
  binding without fusion initiation), followed by the addition of increasing  
  concentrations of GFRT and shift to 37 ºC. The cell-cell fusion decreased  
  to ~60% of the “No treatment” control in the presence of 100nM GFRT  
  and up to 40% in the presence of 200nM and 400nM GFRT. The result  
  indicated that the cell-cell fusion blocking effect of GFRT takes place  
  after virus: cell receptor interaction. Collectively, figures 17 and 18  
  suggested that the inhibitory effect of GFRT on MHV A59 virus is not at  
  the receptor binding stage, but at the fusion event following the receptor  
  binding. 
Conclusion                                                                                                               
  Lectins  are carbohydrate binding agents (CBA) that are being investigated 
  for their anti-viral properties against enveloped viruses [74], and in recent 
  studies, have been shown to be effective against various coronaviruses  
  and other members of the order Nidovirales[79]. Lectins like GFRT can  
  act by binding with glycans on virus surface proteins and preventing the 
   virus-cell interactions required for viral entry[80].This study revealed that 
   though GFRT does not prevent interaction of MHV A59 spike with its  
  receptor CEACAM, it inhibits cell fusion by up to ~60% . Thus, the  
  inhibition of coronavirus entry by GFRT is at the level of post-receptor  
  binding events. MHV A59 spike is a heavily glycosylated protein with 18  
  potential N-glycosylation sites. Figure 19 is a schematic depiction of  
  MHV A59 spike with the putative N-glycosylation sites indicated.  
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Figure 19. Schematic depiction of the putative N-linked glycosylation sites on MHV 
A59 Spike. 
It is possible that GFRT inhibits the fusion events which follow the  
conformational changes of MHV Spike that are associated with receptor 
binding[26]. By binding glycans near the fusion peptide, GFRT could 
obstruct insertion of the fusion peptide into the target cell membrane. It is 
also possible that GFRT binds to glycans in the vicinity of HR1 and HR2 
peptides preventing the formation of the stable six-helix bundle (6HB) 
which draws the viral and cellular membranes close together for fusion to 
occur. Further studies of MHV testing the appearance of 6HB in the 
presence of GFRT may reveal more insight into its site of action. 
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